\"Once DCGI (Drugs Controller General of India) gives us permission to restart the trials in India, we will resume the trials,\" SII CEO Adar Poonawalla said on Saturday

Bharat Biotech says its vaccine candidate was found to generate \"robust immune responses\", thus preventing infection and disease in primates upon high amounts of exposure to live SARS-CoV-2 virus

Delhi Metro resumed its full services on Saturday with the Airport Express Line reopening after a hiatus of over 170 days due to the COVID-19 pandemic; Drug Controller General of India (DCGI) Dr VG Somani has ordered Serum Institute of India (SII) to suspend any new recruitment in Phase 2 and 3 clinical trials for the Oxford-AstraZeneca coronavirus vaccine candidate till further notice; Millions of coronavirus cases may have gone undetected in India earlier this year, a research paper estimates. Watch this and more on News Blast.Also Read: RBI continues to remain net buyer of US dollar in July, purchases $15.973 billion

DCGI VG Somani in his order also asked Serum Institute to suspend any new recruitment in Phase 2 and 3 clinical trials until further notice; SII also need to increase safety monitoring of test subjects vaccinated under trials so far

Unlock 4.0: Delhi metro to follow pre-COVID schedule, Airport Line reopensDelhi Metro resumed its full services on Saturday with the Airport Express Line reopening after a hiatus of over 170 days due to the COVID-19 pandemic. All corridors of the Metro network are now in operation and the timing of services will follow the pre-COVID-19 schedule of 6 AM to 11 PM.DCGI orders Serum Institute to suspend recruitment in Oxford COVID-19 vaccine clinical trialsDrug Controller General of India (DCG...

The DCGI also asked Serum Institute to increase the safety monitoring of the test subjects vaccinated under the trials so far, and submit the plan and report

AstraZeneca on Wednesday \"voluntarily\" paused the phase 3 clinical trials after a volunteer developed an \"unexplained\" illness; in India, Serum Institute, one of the partners of University of Oxford, also decided to pause the trials following the DCGI notice

Phase 2/3 COVID-19 vaccine trials being conducted across 17 sites in India paused till further instructions from regulator; could delay vaccine development process as Serum Institute is front-runner when it comes to companies producing COVID-19 vaccines in India

Public sector bank services at doorstep; govt rolls out new banking featuresFinance Minister Nirmala Sitharaman inaugurated doorstep banking services by public sector banks (PSBs). Banks aim to provide convenience to their customers and at their doorstep through call centre services, web portal and mobile app. Customers would also be able to track their service requests through these channels.DCGI notice to Serum Institute after AstraZeneca halts Oxford COVID-19 vaccine trialsThe central ...

\"We are going by DCGI's direction and so far were not told to pause the trials. If DCGI has any safety concerns, we will follow their instructions and abide by the standard protocols,\" says Serum Institute of India in response to show-cause notice issued by the DCGI

Serum has also started manufacturing the vaccine, targeting to use in India and 92 other countries upon completion of trials and regulatory clearances

\"AstraZeneca has paused the trials due to some unrelated issue with a patient in the UK, and we'll have to wait for AstraZeneca to explain what happened but this is not vaccine-related,\" says Poonawalla

AstraZeneca said that an adverse reaction was observed in one of the volunteers in the UK. According to the pharmaceutical firm, the nature of the adverse reaction remained unknown, though the participant is expected to recover

Dr VK Paul informed the Russian government has approached India to facilitate the Phase-3 trial of their vaccine and also manufacture Sputnik V through Indian companies

Vaccine maker Serum Institute CEO Adar Poonawalla in Fortune's global '40 under 40' listSerum Institute of India (SII) CEO Adar Poonawalla is among the \"emerging leaders\" from across the world named by Fortune in its annual list of 40 most influential people under the age of 40. Byju Raveendran, co-founder of India's leading education technology company Byju's, Reliance Jio Board Directors Isha Ambani, and Akash Ambani are the other young guns from India to feature on the coveted list.App...

The 2020 Fortune 40 under 40 list highlights 40 influential people each in five categories of technology, healthcare, finance, media and entertainment, and government and politics from across the world

COVID-19 vaccine: The University of Oxford and AstraZeneca PLC has developed the first vaccine candidate to start the final round of testing of the coronavirus vaccine

COVID-19 vaccine update: The expert group of the committee, headed by Dr. VK Paul, is also in contact with domestic as well as multinational vaccine makers to understand how soon a COVID-19 vaccine will be ready

Beximco will be the exclusive supplier in Bangladesh for the vaccine being developed by Serum Institute of India (SII), both companies said in a statement on Friday

Coronavirus vaccine: The market for coronavirus vaccine in India could potentially be $6 billion in terms of sales for the coming three years